Novo Nordisk A/S Stock Forecast for 2023 - 2025 - 2030

Updated on 04/21/2024

Stock Rating
12
Price Target
kr960.00
Consensus
Outperform
Upside
10.83%
Analysts
14
Stock Rating
12
Upside
10.83%
Analysts
14
Price Target
kr960.00

Novo Nordisk A/S Stock Forecast and Price Target

If the average price target of kr960.00 set by fourteen distinguished experts for Novo Nordisk A/S over the past few weeks is reached this year, there would be a potential upside of approximately 10.83% from the last closing price in April, 2024. This potential increase is based on a high estimate of kr1120.00 and a low estimate of kr530.00. If you're thinking of investing in NOVO B stock, it's critical to check out its competitors as well.

kr960.00

10.83% Upside

Outperform
Outperform

Novo Nordisk A/S Fair Value Forecast for 2023 - 2025 - 2030

In the last four years, Novo Nordisk A/S's Price has decreased by 100.00%, from kr357.34 to kr0.00. Analysts predict that Novo Nordisk A/S's Fair Value will increase in the upcoming year, reaching kr869.35. This would represent an increase of 100.00%. Over the next seven years, experts predict that Novo Nordisk A/S's Fair Value will grow at a rate of 100.00%.

2024 Fair Value Forecast
kr869.35
2025 Fair Value Forecast
kr1.02k
2026 Fair Value Forecast
kr1.17k
2027 Fair Value Forecast
kr1.25k
2028 Fair Value Forecast
kr1.29k
2029 Fair Value Forecast
kr1.21k
2030 Fair Value Forecast
kr1.33k
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 9
$147.91 Buy/Sell $174.55 14.93%
MRK Stock Forecast Merck Outperform 2
$125.78 Buy/Sell $130.51 10.91%
AZN Stock Forecast AstraZeneca PLC Outperform 17
£109.46 Buy/Sell £165.99 47.83%
NOVN Stock Forecast Novartis Hold 10
CHF85.53 Buy/Sell CHF105.00 23.11%
ROG Stock Forecast Roche Holding Hold 16
CHF222.10 Buy/Sell CHF307.83 22.69%

Novo Nordisk A/S Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Novo Nordisk A/S's Revenue has seen an increase, rising from kr126.95B to kr232.26B. This represents a growth of 82.96%. Analysts predict that Novo Nordisk A/S's Revenue will increase in the upcoming year, reaching kr275.75B. This would represent an increase of 18.72%. Over the next eight years, experts predict that Novo Nordisk A/S's Revenue will grow at a rate of 126.01%.

2024 Rev Forecast
kr275.75B
2024 Rev Forecast
kr275.75B
2025 Rev Forecast
kr319.56B
2026 Rev Forecast
kr364.06B
2027 Rev Forecast
kr385.89B
2028 Rev Forecast
kr440.66B
2029 Rev Forecast
kr487.59B
2030 Rev Forecast
kr524.93B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ABT Stock Forecast Abbott Laboratories Outperform 9
$107.28 Buy/Sell $118.92 18.38%
PFE Stock Forecast Pfizer Outperform 2
$26.00 Buy/Sell $32.87 17.31%
AMGN Stock Forecast Amgen Outperform 4
$268.93 Buy/Sell $303.65 17.97%

Novo Nordisk A/S Dividend per Share Forecast for 2023 - 2025 - 2030

Novo Nordisk A/S's Dividend per Share has seen growth In the last three years, going from kr9.10 to kr9.40 – a gain of 3.30% In the next year, analysts believe that Dividend per Share will reach kr10.50 – an increase of 11.70%. For the next seven years, the forecast is forDividend per Share to grow by 41.38%.

2024 DPS Forecast
kr10.50
2025 DPS Forecast
kr12.28
2026 DPS Forecast
kr13.40
2027 DPS Forecast
kr14.42
2028 DPS Forecast
kr10.99
2029 DPS Forecast
kr12.08
2030 DPS Forecast
kr13.29
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
SAN Stock Forecast Sanofi Outperform 16
86.89€ Buy/Sell 102.80€ 24.30%
MDT Stock Forecast Medtronic Outperform 11
$79.48 Buy/Sell $92.47 20.16%
BMY Stock Forecast Bristol-Myers Squibb Hold 2
$48.93 Buy/Sell $58.15 12.41%

Novo Nordisk A/S Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
kr84.01B
2025 FCF Forecast
kr99.88B
2026 FCF Forecast
kr102.70B
2027 FCF Forecast
kr105.80B
2028 FCF Forecast
kr109.70B
2029 FCF Forecast
kr117.77B
2030 FCF Forecast
kr127.83B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BSX Stock Forecast Boston Scientific Outperform 11
$67.33 Buy/Sell $70.14 8.42%
CSL Stock Forecast CSL Outperform 12
$269.49 Buy/Sell $205.51 -24.61%
GILD Stock Forecast Gilead Sciences Inc Outperform 11
$66.76 Buy/Sell $87.82 19.83%

Novo Nordisk A/S EBITDA Forecast for 2023 - 2025 - 2030

Novo Nordisk A/S's EBITDA has grown in the last three years, jumping from kr58.58B to kr109.81B – an increase of 87.45%. In the next year, analysts predict that EBITDA will reach kr133.70B – an increase of 21.75%. For the next seven years, the forecast is for EBITDA to grow by 111.62%.

2024 EBITDA Forecast
kr133.70B
2025 EBITDA Forecast
kr157.72B
2026 EBITDA Forecast
kr178.04B
2027 EBITDA Forecast
kr184.52B
2028 EBITDA Forecast
kr203.83B
2029 EBITDA Forecast
kr217.77B
2030 EBITDA Forecast
kr232.39B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
GSK Stock Forecast GSK Outperform 12
£15.99 Buy/Sell £17.30 21.95%
SHW Stock Forecast Sherwin Williams Outperform 15
$305.96 Buy/Sell $317.38 11.04%
4568 Stock Forecast Daiichi Sankyo Company Buy 4
¥4.64k Buy/Sell ¥5.24k 25.11%

Novo Nordisk A/S EBIT Forecast for 2023 - 2025 - 2030

In the last three years, Novo Nordisk A/S's EBIT has increased by 90.89%, going from kr54.48B to kr103.99B. In the next year, analysts are expecting an increase in EBIT, predicting it will reach kr122.82B – an increase of 18.11%. The Novo Nordisk A/S forecast is for EBIT to reach kr293.75B or grow by 182.48%.

2024 EBIT Forecast
kr122.82B
2024 EBIT Forecast
kr122.82B
2025 EBIT Forecast
kr144.67B
2026 EBIT Forecast
kr168.77B
2027 EBIT Forecast
kr182.23B
2028 EBIT Forecast
kr225.10B
2029 EBIT Forecast
kr272.20B
2030 EBIT Forecast
kr293.75B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
4502 Stock Forecast Takeda Pharmaceutical Company Outperform 5
¥4.07k Buy/Sell ¥4.74k 11.82%
PPG Stock Forecast PPG Industries Outperform 13
$130.90 Buy/Sell $159.04 21.01%
BIIB Stock Forecast Biogen Outperform 10
$194.38 Buy/Sell $299.62 50.22%

Novo Nordisk A/S EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, Novo Nordisk A/S's EPS has decreased by 100.00%, from kr9.01 to kr0.00. Analysts predict that Novo Nordisk A/S's EPS will increase in the upcoming year, reaching kr21.92. This would represent an increase of 100.00%. Over the next seven years, experts predict that Novo Nordisk A/S's EPS will grow at a rate of 100.00%.

2024 EPS Forecast
kr21.92
2025 EPS Forecast
kr25.83
2026 EPS Forecast
kr29.43
2027 EPS Forecast
kr31.43
2028 EPS Forecast
kr32.58
2029 EPS Forecast
kr30.50
2030 EPS Forecast
kr33.60
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BAYN Stock Forecast Bayer Hold 5
26.33€ Buy/Sell 45.15€ 21.53%
HZNP Stock Forecast Horizon Therapeutics Public - 16
$115.69 Buy/Sell $116.50 -100.00%
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$144.41 Buy/Sell $245.24 48.88%